Compare MGYR & MXCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MGYR | MXCT |
|---|---|---|
| Founded | 1922 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 112.7M | 129.6M |
| IPO Year | 2021 | 2021 |
| Metric | MGYR | MXCT |
|---|---|---|
| Price | $17.20 | $1.19 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.50 |
| AVG Volume (30 Days) | 3.6K | ★ 902.6K |
| Earning Date | 04-23-2026 | 05-12-2026 |
| Dividend Yield | ★ 2.30% | N/A |
| EPS Growth | ★ 26.83 | N/A |
| EPS | ★ 0.98 | N/A |
| Revenue | N/A | ★ $33,026,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $18.50 |
| P/E Ratio | $18.52 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $16.00 | $0.64 |
| 52 Week High | $20.00 | $2.37 |
| Indicator | MGYR | MXCT |
|---|---|---|
| Relative Strength Index (RSI) | 65.58 | 61.43 |
| Support Level | $16.96 | $1.08 |
| Resistance Level | $18.88 | $1.30 |
| Average True Range (ATR) | 0.17 | 0.07 |
| MACD | 0.08 | -0.01 |
| Stochastic Oscillator | 100.00 | 60.47 |
Magyar Bancorp Inc is an independent, community financial services provider offering traditional banking services to individual, business, and government customers. The Company attracts retail deposits through its main office in New Brunswick, New Jersey, and branch offices in Middlesex and Somerset Counties, and invests those funds mainly in commercial and residential real estate loans, commercial business loans, SBA loans, home equity loans and lines of credit, construction and land loans, and investment securities. Revenues are derived mainly from interest on loans and securities and from fees and service charges, with lending relationships focused on small to mid-sized businesses and individual consumers in central and northern New Jersey.
MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.